Company Overview of Hospira Inc.
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment o...
275 North Field Drive
Lake Forest, IL 60045
Founded in 2003
Key Executives for Hospira Inc.
Chief Financial Officer and Senior Vice President of Finance
Senior Vice President of Operations
President of Hospira Medical Devices
President of US Operations
Chief Scientific Officer and Senior Vice President
Compensation as of Fiscal Year 2015.
Hospira Inc. Key Developments
Pfizer Reportedly Mulls Sale Of Hospira Infusion Pump Business
Jan 13 16
Pfizer Inc. (NYSE:PFE) may sell some asset. Bloomberg reported, citing people familiar with the matter as saying that the company is thinking about selling Hospira Inc.'s infusion pump business for about $2 billion. Bloomberg reported that talks are said to be at an early stage. According to the news report, a Pfizer spokeswoman declined to comment.
Hospira Secures Indian Patent for Drug
Oct 17 15
Hospira, now a subsidiary of Pfizer Inc, has secured an Indian patent for an improved process for the preparation of Cilastatin -part of a medical compound used in the treatment of a number of bacterial infections. Cilastatin is a chemical which acts with antibiotic Imipenem for the treatment of infections of various body systems. Imipenem and Cilastatin combined in a drug is an antibiotic. It is used to treat serious infections that are mild to moderate in severity, such as lower respiratory infection and heart valve infection. The Imipenem-Clastatin intravenous drugs are marketed under common brand name Primaxin. The patent application titled 'an improved process for the preparation of Cilastatin' was originally filed by Chennai-based Orchid Chemicals and Pharmaceuticals in 2005. With some business of Orchid Pharma having been taken over by Hospira, in 2009, the patent application under process was also transferred to Hospira. Hospira was recently acquired by Pfizer. Cilastatin, a renal dipeptidase inhibitor, triggers the enzymatic breakdown of Imipenem and increases urinary excretion of the active drug. Originally Cilastatin was disclosed in a US patent and it also discloses various processes for the preparation of Cilastatin. The primary objective of the instant invention - which has now been granted patent - is to provide a commercial process for the preparation of Cilastatin. The invention also offers to provide an improved process for the preparation Cilastatin Sodium with high purity.
Hospira, Inc. and Cerner Corporation Expand Agreement to Enhance I.V.-EMR Interoperability
Sep 9 15
Hospira Inc. and Cerner Corporation have expanded their agreement to advance the integration of I.V.-EMR technology. The expanded agreement strengthens both companies' ability to continue to bring innovative technologies to market, designed to enhance interoperability between Hospira's smart intravenous (I.V.) infusion devices and Cerner's CareAware solutions to meet the evolving needs of healthcare organizations. Cerner's CareAware technology is supplier-neutral and enables interoperability among medical devices, healthcare applications and electronic medical record (EMR) platforms. With Cerner's CareAware programming, Hospira will connect its infusion pumps to the EMR at the point of care and add functionality for devices connecting to CareAware.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|